We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Amgen Inc | TG:AMGN | Tradegate | Bond |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.125 | -0.13% | 97.07 | 97.01 | 97.13 | 0 | 22:50:21 |
From Jun 2019 to Jun 2024
By Val Brickates Kennedy
Drug stocks inched up in early action Monday as shares of DepoMed Inc. (DEPO) sank after it released mixed Phase III clinical data for its menopausal hot-flash treatment Serada.
Both the NYSE Pharmaceutical Index (DRG) and the NYSE Arca Biotechnology Index (BTK) were up marginally at 290.98 and 915.93, respectively.
Shares of DepoMed were down around 34% at $4.18.
Early Monday, DepoMed reported mixed preliminary Phase III data for its Serada. The company said despite the results, it remains hopeful about the program and plans to discuss a potential approval path for the menopausal hot-flash treatment product with U.S. regulators.
Shares of Amgen Inc. (AMGN) were up over 1% at $60.22. Analysts at UBS raised their rating of the stock to buy.
Onyx Pharmaceuticals (ONXX) shares climbed 6% to $28.52. The biotech group said it was buying privately-held Proteolix Inc. for $276 million upfront, plus milestone payments down the road.
-By Val Brickates Kennedy, 415-439-6400; AskNewswires@dowjones.com
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
